95 related articles for article (PubMed ID: 26170397)
1. CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy.
Poret N; Fu Q; Guihard S; Cheok M; Miller K; Zeng G; Quesnel B; Troussard X; Galiègue-Zouitina S; Shelley CS
Cancer Res; 2015 Sep; 75(18):3902-11. PubMed ID: 26170397
[TBL] [Abstract][Full Text] [Related]
2. Underexpression of RhoH in Hairy Cell Leukemia.
Galiègue-Zouitina S; Delestré L; Dupont C; Troussard X; Shelley CS
Cancer Res; 2008 Jun; 68(12):4531-40. PubMed ID: 18559497
[TBL] [Abstract][Full Text] [Related]
3. Deeper, longer phenotyping to accelerate the discovery of the genetic architectures of diseases.
Kohane IS
Genome Biol; 2014; 15(5):115. PubMed ID: 25165795
[No Abstract] [Full Text] [Related]
4. Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-γ by a T-bet-dependent mechanism.
Bürgler S; Gimeno A; Parente-Ribes A; Wang D; Os A; Devereux S; Jebsen P; Bogen B; Tjønnfjord GE; Munthe LA
J Immunol; 2015 Jan; 194(2):827-35. PubMed ID: 25505279
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 7 cooperates with IL-4 in activated B cells through antigen receptor or CD38 and induces class switch recombination and IgG1 production.
Tsukamoto Y; Nagai Y; Kariyone A; Shibata T; Kaisho T; Akira S; Miyake K; Takatsu K
Mol Immunol; 2009 Apr; 46(7):1278-88. PubMed ID: 19157556
[TBL] [Abstract][Full Text] [Related]
6. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
7. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
8. CD38 at the junction between prognostic marker and therapeutic target.
Deaglio S; Aydin S; Vaisitti T; Bergui L; Malavasi F
Trends Mol Med; 2008 May; 14(5):210-8. PubMed ID: 18403265
[TBL] [Abstract][Full Text] [Related]
9. CD52 expression in hairy cell leukemia.
Quigley MM; Bethel KJ; Sharpe RW; Saven A
Am J Hematol; 2003 Dec; 74(4):227-30. PubMed ID: 14635201
[TBL] [Abstract][Full Text] [Related]
10. Repression of the RHOH gene by JunD.
Delestré L; Berthon C; Quesnel B; Figeac M; Kerckaert JP; Galiègue-Zouitina S; Shelley CS
Biochem J; 2011 Jul; 437(1):75-88. PubMed ID: 21473742
[TBL] [Abstract][Full Text] [Related]
11. Identification and functional characterization of the hepatic stellate cell CD38 cell surface molecule.
March S; Graupera M; Rosa Sarrias M; Lozano F; Pizcueta P; Bosch J; Engel P
Am J Pathol; 2007 Jan; 170(1):176-87. PubMed ID: 17200192
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
13. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
14. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
[TBL] [Abstract][Full Text] [Related]
15. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.
Zucchetto A; Benedetti D; Tripodo C; Bomben R; Dal Bo M; Marconi D; Bossi F; Lorenzon D; Degan M; Rossi FM; Rossi D; Bulian P; Franco V; Del Poeta G; Deaglio S; Gaidano G; Tedesco F; Malavasi F; Gattei V
Cancer Res; 2009 May; 69(9):4001-9. PubMed ID: 19383907
[TBL] [Abstract][Full Text] [Related]
16. A membrane antigen (HC1) selectively present on hairy cell leukemia cells, endothelial cells, and epidermal basal cells.
Posnett DN; Marboe CC; Knowles DM; Jaffe EA; Kunkel HG
J Immunol; 1984 Jun; 132(6):2700-2. PubMed ID: 6609956
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
18. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells.
Vaisitti T; Aydin S; Rossi D; Cottino F; Bergui L; D'Arena G; Bonello L; Horenstein AL; Brennan P; Pepper C; Gaidano G; Malavasi F; Deaglio S
Leukemia; 2010 May; 24(5):958-69. PubMed ID: 20220774
[TBL] [Abstract][Full Text] [Related]
19. B-cell growth factor-induced and alpha-interferon-inhibited proliferation of hairy cells coincides with modulation of cell surface antigens.
Gamliel H; Brownstein BH; Gurfel D; Wu SH; Rosner MC; Golomb HM
Cancer Res; 1990 Jul; 50(13):4111-20. PubMed ID: 2354460
[TBL] [Abstract][Full Text] [Related]
20. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.
Dürig J; Naschar M; Schmücker U; Renzing-Köhler K; Hölter T; Hüttmann A; Dührsen U
Leukemia; 2002 Jan; 16(1):30-5. PubMed ID: 11840260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
